ArticleInternational urology and nephrology2025
Efficacy and safety of intravesical alkalinized lignocaine for cystoscopy: a retrospective analysis.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo study the effect of intravesical instillation of alkalinized lignocaine (AL) solution on pain scores and patient tolerance in patients undergoing cystoscopy. Bladder distension, trigonal irritation, and bladder neck irritation during cystoscopy under local anesthesia contribute significantly to patient discomfort.
methodsThis was a retrospective case-control study performed at a single center from January 2023 to July 2023 (Institutional Ethics Committee approval: T/IM-NF/Urol/23/194). Prior to cystoscopy, patients in control group (Group A) (LG group) received only 10 ml of 2% lignocaine HCl gel (LG) per-urethrally, while intervention group (Group B) (AL group) also received 30 ml of AL solution intravesically (20 min prior). Postoperative pain scores were compared using visual analog scale (VAS). The patient tolerance, postoperative hematuria, experience with the procedure, persistent LUTS, and incidence of UTI after 1 week were also compared.
resultsThe study included 50 male patients in each group undergoing cystoscopy for LUTS under evaluation, unexplained hematuria and check cystoscopy for Ca bladder; the median age was comparable between the groups. The VAS scores at 0 h [2(2-3) vs. 5(4-5); p < 0.001], 1 h [1(1-2) vs. 3(3-4); p < 0.001], and 2 h [0 vs. 1(1-1); p < 0.001] were better in Group B. Patient tolerance and experience with the procedure, assessed 1 week postoperatively, were significantly better in Group B. Postoperative clinical features and incidence of LUTS at 1 week postoperatively were significantly less in Group B.
conclusionUsing intravesical AL solution significantly reduces pain and improves patient tolerance and satisfaction during cystoscopy; also, it is safe and well-tolerated.
Indexed as
Identifiers
39915424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.